“Almost Bleeding to Death”: The Conundrum of Acquired Amegakaryocytic Thrombocytopenia
-
- Gabrielle Elena Brown
- University of Arizona College of Medicine, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
-
- Hani M. Babiker
- Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
-
- Carlos L. Cantu
- Department of Pathology, University of Arizona College of Medicine, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
-
- Andrew M. Yeager
- Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
-
- Ravitharan Krishnadasan
- Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
この論文をさがす
説明
<jats:p>Acquired amegakaryocytic thrombocytopenia (AAT) is a rare hematological disorder causing severe thrombocytopenia and bleeding. Previous in vitro studies postulated both cell-mediated suppression of megakaryocytopoiesis in early megakaryocytic progenitor cells and humoral-mediated suppression by anti-thrombopoietin antibodies as possible etiologies of AAT. Patients with AAT usually present with severe bleeding and thrombocytopenia that is unresponsive to steroids and intravenous immunoglobulin (IVIG). Although standard guidelines have not been established for management of AAT, a few case reports have indicated a response to immunosuppressive treatment. The prompt recognition of this disease entity is essential in view of the substantial risk of morbidity and mortality from excessive bleeding. We report a case of AAT successfully treated with equine antithymocyte globulin (ATG) and cyclosporine (CSP).</jats:p>
収録刊行物
-
- Case Reports in Hematology
-
Case Reports in Hematology 2014 1-5, 2014
Hindawi Limited
